Category: Business

Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018

PALO ALTO, Calif.–(BUSINESS WIRE)–Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, is pleased to announce the latest liquidity events for eight (8) of its portfolio companies: DocuSign, Inc., Tricida, Inc. and BridgeBio Inc./Eidos Therapeutics, Inc., which recently completed their initial public offerings (“IPO”); and Inotek Pharmaceuticals Corporati

Ocular Therapeutix™ Announces NDA Resubmission of DEXTENZA™

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate DEXTENZA™ (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmiss

BioTime Awarded Grant From the NIH

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). This award constitutes the second-year funding of a $1.6 million SBIR grant to advance BioTime’s innovative, next generation retinal restoration program addressing advanced retinal diseases an

Novaliq’s NovaTears® Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealand

HEIDELBERG, Germany–(BUSINESS WIRE)–#AFT–Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is a chronic condition affecting about one third of Australian adults and half of those aged over 50. At a minimum, dry e

STAAR Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreement

MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, and Kobe Kanagawa Eye Clinic with locations in Tokyo and Osaka, today announced they have entered into a multi-year Strategic Cooperation Agreement to provide STAAR’s EVO Visian ICL™ lenses as a primary and premium option for patients seeking visual freedom from spectacles and contact lenses through refractive